Literature DB >> 34173882

Synthesis, structure and anticancer properties of new biotin- and morpholine-functionalized ruthenium and osmium half-sandwich complexes.

Mickaël Marloye1, Haider Inam2, Connor J Moore2, Vinciane Debaille3, Justin R Pritchard2, Michel Gelbcke1, Franck Meyer1, François Dufrasne1, Gilles Berger4,5.   

Abstract

Ruthenium (Ru) and osmium (Os) complexes are of sustained interest in cancer research and may be alternative to platinum-based therapy. We detail here three new series of ruthenium and osmium complexes, supported by physico-chemical characterizations, including time-dependent density functional theory, a combined experimental and computational study on the aquation reactions and the nature of the metal-arene bond. Cytotoxic profiles were then evaluated on several cancer cell lines although with limited success. Further investigations were, however, performed on the most active series using a genetic approach based on RNA interference and highlighted a potential multi-target mechanism of action through topoisomerase II, mitotic spindle, HDAC and DNMT inhibition.
© 2021. Society for Biological Inorganic Chemistry (SBIC).

Entities:  

Keywords:  Anticancer complex; Cell targeting; Metallodrug; Metal–arene; shRNA profiling

Year:  2021        PMID: 34173882     DOI: 10.1007/s00775-021-01873-9

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  34 in total

1.  INHIBITION OF CELL DIVISION IN ESCHERICHIA COLI BY ELECTROLYSIS PRODUCTS FROM A PLATINUM ELECTRODE.

Authors:  B ROSENBERG; L VANCAMP; T KRIGAS
Journal:  Nature       Date:  1965-02-13       Impact factor: 49.962

2.  Organometallic osmium arene complexes with potent cancer cell cytotoxicity.

Authors:  Ying Fu; Abraha Habtemariam; Ana M Pizarro; Sabine H van Rijt; David J Healey; Patricia A Cooper; Steven D Shnyder; Guy J Clarkson; Peter J Sadler
Journal:  J Med Chem       Date:  2010-10-26       Impact factor: 7.446

3.  Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy.

Authors:  Suzanne Leijen; Sjaak A Burgers; Paul Baas; Dick Pluim; Matthijs Tibben; Erik van Werkhoven; Enzo Alessio; Gianni Sava; Jos H Beijnen; Jan H M Schellens
Journal:  Invest New Drugs       Date:  2014-10-25       Impact factor: 3.850

Review 4.  Structure-activity relationships for ruthenium and osmium anticancer agents - towards clinical development.

Authors:  Samuel M Meier-Menches; Christopher Gerner; Walter Berger; Christian G Hartinger; Bernhard K Keppler
Journal:  Chem Soc Rev       Date:  2018-02-05       Impact factor: 54.564

5.  In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes.

Authors:  Claudine Scolaro; Alberta Bergamo; Laura Brescacin; Riccarda Delfino; Moreno Cocchietto; Gábor Laurenczy; Tilmann J Geldbach; Gianni Sava; Paul J Dyson
Journal:  J Med Chem       Date:  2005-06-16       Impact factor: 7.446

Review 6.  Molecular mechanisms of cisplatin resistance.

Authors:  L Galluzzi; L Senovilla; I Vitale; J Michels; I Martins; O Kepp; M Castedo; G Kroemer
Journal:  Oncogene       Date:  2011-09-05       Impact factor: 9.867

7.  Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma.

Authors:  Jenifer B Gifford; Wei Huang; Ann E Zeleniak; Antreas Hindoyan; Hong Wu; Timothy R Donahue; Reginald Hill
Journal:  Mol Cancer Ther       Date:  2016-03-03       Impact factor: 6.261

8.  A tumor-targeting and lysosome-specific two-photon fluorescent probe for imaging pH changes in living cells.

Authors:  Baoli Dong; Xuezhen Song; Xiuqi Kong; Chao Wang; Nan Zhang; Weiying Lin
Journal:  J Mater Chem B       Date:  2017-01-17       Impact factor: 6.331

9.  Molecular mode of action of NKP-1339 - a clinically investigated ruthenium-based drug - involves ER- and ROS-related effects in colon carcinoma cell lines.

Authors:  Lea S Flocke; Robert Trondl; Michael A Jakupec; Bernhard K Keppler
Journal:  Invest New Drugs       Date:  2016-03-18       Impact factor: 3.850

10.  In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer.

Authors:  R E Aird; J Cummings; A A Ritchie; M Muir; R E Morris; H Chen; P J Sadler; D I Jodrell
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.